The RESTORE-G real-world study investigated the intensification strategies following GLP1-RA therapy failure in type 2 diabetes. Dr Riccardo Candido (Diabetes Center District 4, ASUGI, Trieste, Italy) discusses the design of the study, the key findings and the implications for clinical practice.
The abstract entitled ‘Treatment Intensification after Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes—The RESTORE-G Real-World Study’ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
- How did the RESTORE-G real-world study investigate intensification strategies following GLP1-RA therapy failure? (0:22)
- What were the key findings of the study including the main intensification approaches and clinical outcomes with these approaches? (1:57)
- In your opinion, what are the implications of these results for clinical practice? (4:35)
Disclosures: Riccardo Candido has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
Share this Video
Related Videos In Diabetes
Clipper Young & Shirley Wong, ADCES 2022: New horizons in type 2 diabetes management and cardiorenal risk reduction: A pharmacotherapeutic update
Cardiorenal complications in people with type 2 diabetes illustrates a link between the heart and the kidneys, which can be exacerbated by other comorbidities, such as hypertension, dyslipidaemia, and obesity. In this touchENDOCRINOLOGY interview, Dr Clipper Young and Shirley Wong (Touro University California College of Osteopathic Medicine, Vallejo, CA, USA) firstly discuss diabetes management and […]
Jennifer Clements, ADCES 2022: Efficacy and safety of once-daily vs twice-daily insulin glargine in non-critically ill patients with diabetes
In this touchENDOCRINOLOGY interview, Prof. Jennifer Clements (University of South Carolina, College of Pharmacy, Columbia, SC, USA) joins us to discuss a study investigating the efficacy and safety of once-daily vs twice-daily insulin glargine in non-critically ill patients. The abstract entitled: ‘A Retrospective Analysis of Once-daily versus Twice-daily Dosing of Insulin Glargine in Non-critically Ill […]
Jennifer Clements, ADCES 2022: Clinical implications of SGLT-2 inhibitors for chronic kidney disease in people with type 2 diabetes
Chronic kidney disease in people with type 2 diabetes is heavily prevalent, and the main causes are diabetes and hypertension. In this touchENDOCRINOLOGY interview, Prof. Jennifer Clements (University of South Carolina, College of Pharmacy, Columbia, SC, USA) joins us to discuss the health burden of chronic kidney disease (CKD) in people with type 2 diabetes, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!